Pallab Mandal | Pharmacology | Best Innovation Award

Published on 17/10/202617/10/2026 by Top Pharmaceutical

Best Innovation Award

Pallab Mandal – Ami Polymer Pvt Ltd

Pallab Mandal
Affiliation	Ami Polymer Pvt Ltd
Country	India
Scopus ID	57190006013
Documents	17
Citations	88
h-index	6
Subject Area	Pharmacology
Event	International Top Pharmaceutical Awards
ORCID	0000-0003-3869-7678

Pallab Mandal is a pharmaceutical research scientist associated with bioanalytical research, drug analysis, and pharmacokinetic investigations. This academic recognition profile summarizes his documented research activities and publication record in pharmacology and pharmaceutical analysis. According to his ORCID record, Mandal’s research interests include liquid chromatography tandem mass spectrometry, pharmacokinetics, pharmacodynamics, bioequivalence studies, drug analysis in human plasma, metabolite analysis, and protein analysis. His listed professional activities also include bioanalytical research, university teaching, and pharmaceutical association membership. [1]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

Pallab Mandal’s documented publications address pharmaceutical analysis, analytical method development, bioanalytical validation, and pharmacokinetic investigations. His work includes the application of liquid chromatography tandem mass spectrometry to pharmaceutical compounds and biological samples. These research themes provide the academic context for considering his profile for the Best Innovation Award. The article summarizes available records without asserting an independently confirmed award decision. [1]

Keywords

Pallab Mandal, Best Innovation Award, pharmacology, bioanalysis, LC-MS/MS, bioequivalence, pharmaceutical analysis, pharmacokinetics, analytical method validation, drug development.

Introduction

Pharmaceutical research depends on reliable analytical procedures to identify and quantify drug compounds. Validated bioanalytical methods support the measurement of substances in biological samples and can contribute to pharmacokinetic and bioequivalence investigations. Mandal’s publication record addresses these areas through analytical methods developed for a range of pharmaceutical compounds. [2]

Research Profile

The supplied ORCID record identifies Mandal as an LC-MS/MS bioanalyst and research scientist involved in bioequivalence studies. It records professional bioanalytical employment beginning in 2015, university-related teaching activity, and postgraduate research affiliation. His professional record also lists membership in the Indian Pharmaceutical Association. [1]

Research Contributions

Mandal’s listed studies investigate analytical approaches for compounds including miltefosine, azelnidipine, vilazodone, diosmetin, hesperetin, metformin, and teneligliptin. Several publications describe LC-MS/MS methods for human plasma analysis and pharmacokinetic applications. His research record also includes work on pharmaceutical packaging and drug-analysis procedures, reflecting interests in analytical reliability and pharmaceutical practice. [2] [3]

Publications

Representative publications listed in his ORCID record include a pharmaceutical packaging audit published in 2022, a miltefosine analytical method study from 2022, an azelnidipine bioanalytical method study from 2022, a vilazodone quantification study from 2021, and a diosmetin and hesperetin analysis from 2019. The DOI links in the references provide direct access to these bibliographic records and their available publication details. [4] [5]

Research Impact

The supplied profile metrics report 17 documents, 88 citations, and an h-index of 6. These figures are provided for this article and have not been independently verified against a live database. Citation counts may change over time or differ between platforms. The publication topics indicate potential practical relevance to pharmaceutical analysis, although individual findings should be assessed through their methods, results, and reproducibility. [1]

Award Suitability

Mandal’s research themes provide a basis for consideration in a pharmaceutical innovation recognition category. A comprehensive assessment should examine methodological originality, reproducibility, practical application, documented individual contributions, and independent peer review. The listed publications establish relevant research activity, but award eligibility and final selection remain matters for the award organizers and their evaluation process.

Conclusion

Pallab Mandal’s research profile focuses on pharmaceutical bioanalysis, LC-MS/MS-based analytical methods, and pharmacokinetic applications. His listed publications cover multiple drug compounds and related pharmaceutical topics. This Best Innovation Award article presents a structured academic overview with linked researcher records and DOI references for readers seeking to examine the available evidence independently.

External Links

References

ORCID. (n.d.). Pallab Mandal: Researcher record and works. ORCID. https://orcid.org/0000-0003-3869-7678
Mandal, P., et al. (2022). An audit on design of pharmaceutical packaging. Journal of Packaging Technology and Research. https://doi.org/10.1007/s41783-022-00141-8
Mandal, P., et al. (2022). Analytical method development and validation of miltefosine by liquid chromatography tandem mass spectrometry. Research Journal of Pharmacy and Technology. https://doi.org/10.52711/0974-360x.2022.00693
Mandal, P., et al. (2022). A novel validated bioanalytical method for azelnidipine in Indian human plasma by LC-MS/MS. Indian Drugs. https://doi.org/10.53879/id.59.05.12787
Mandal, P., et al. (2021). Determination and quantitation of vilazodone hydrochloride in human plasma by LC-ESI-MS/MS. Journal of Analytical & Pharmaceutical Research. https://doi.org/10.15406/japlr.2021.10.00361

Shalini Singh | Clinical Pharmacology | Women Researcher Award

Published on 04/08/202604/08/2026 by Top Pharmaceutical

Women Researcher Award

Shalini Singh
Global Cosmetic Regulatory Services Pvt Ltd, India

Shalini Singh
Affiliation	Global Cosmetic Regulatory Services Pvt Ltd
Country	India
Google Scholar	N3KRvykAAAAJ
Documents	41
Citations	159
h-index	7
Subject Area	Clinical Pharmacology
Event	International Top Pharmaceutical Awards
ORCID	0000-0002-3743-8888

Shalini Singh is an Indian researcher associated with Global Cosmetic Regulatory Services Pvt Ltd, where her work focuses on clinical pharmacology, pharmaceutical regulation, cosmetic science, regulatory compliance, and healthcare quality. Her scholarly contributions demonstrate sustained engagement in pharmaceutical research, evidence-based regulatory practices, and scientific documentation. Through peer-reviewed publications and collaborative investigations, she has contributed to improving regulatory understanding and pharmaceutical safety within both academic and industrial environments.[1] Her research profile reflects interdisciplinary expertise spanning clinical pharmacology, pharmaceutical sciences, cosmetic regulation, and healthcare innovation.[2]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

Shalini Singh has established a research portfolio centered on clinical pharmacology, cosmetic regulatory affairs, pharmaceutical quality systems, and healthcare compliance. Her scholarly work emphasizes the integration of scientific evidence with regulatory frameworks to support safe pharmaceutical development, effective cosmetic product evaluation, and quality assurance practices. Through published research and professional collaborations, she has contributed to advancing regulatory science while promoting responsible innovation across pharmaceutical and cosmetic industries. Her publication record, citation profile, and continued academic engagement indicate consistent participation in multidisciplinary pharmaceutical research.[1][3]

Keywords

Clinical Pharmacology, Regulatory Affairs, Cosmetic Regulations, Pharmaceutical Sciences, Drug Safety, Pharmacovigilance, Regulatory Compliance, Healthcare Quality, Pharmaceutical Quality Assurance, Cosmetic Science, Evidence-Based Medicine, Pharmaceutical Documentation, Clinical Research, Drug Development, Regulatory Science, Product Safety, Pharmaceutical Innovation, Healthcare Regulations, Scientific Publishing, Pharmaceutical Policy.

Introduction

Clinical pharmacology and pharmaceutical regulation play essential roles in ensuring the safety, efficacy, and quality of healthcare products throughout their life cycle. Researchers working in these fields contribute to scientific advancement by strengthening regulatory systems, supporting evidence-based decision-making, and improving public health outcomes. Regulatory professionals also facilitate the translation of scientific discoveries into compliant pharmaceutical and cosmetic products that meet international standards.[2]

Research Profile

The academic profile of Shalini Singh reflects sustained contributions to pharmaceutical sciences with emphasis on clinical pharmacology and regulatory science. Her scholarly metrics include forty-one indexed publications, one hundred fifty-nine citations, and an h-index of seven, indicating continued academic visibility and citation impact within her research community.[1]

Research Contributions

Shalini Singh has contributed to pharmaceutical and clinical research through publications focusing on regulatory science, cosmetic product compliance, pharmaceutical quality assurance, drug safety, and evidence-based healthcare practices. Her research supports the development of scientifically validated regulatory frameworks while encouraging harmonization between pharmaceutical innovation and international compliance standards.[2][3]

Publications

The publication portfolio of Shalini Singh demonstrates continuous scholarly activity within pharmaceutical sciences and clinical pharmacology. Her research output includes peer-reviewed articles addressing regulatory science, pharmaceutical development, healthcare quality, cosmetic regulations, and related multidisciplinary areas. Collectively, these publications have contributed to academic discussions concerning pharmaceutical quality assurance and regulatory compliance.[1]

Research Impact

The measurable research impact of Shalini Singh is reflected through publication productivity, citation performance, and continuing engagement with pharmaceutical and regulatory research communities. Her work contributes to scientific understanding of clinical pharmacology, pharmaceutical quality systems, cosmetic regulation, and healthcare policy. Citation indicators demonstrate that her publications have been referenced by subsequent investigations, supporting ongoing knowledge development within pharmaceutical sciences.[1][2]

Award Suitability

Based on her documented publication record, research activity, citation profile, and professional engagement within clinical pharmacology and pharmaceutical regulation, Shalini Singh demonstrates characteristics commonly associated with recognition under the Women Researcher Award presented at the International Top Pharmaceutical Awards. Her contributions illustrate sustained scholarly participation, interdisciplinary collaboration, and commitment to advancing pharmaceutical sciences through research and regulatory excellence.[1][3]

Conclusion

Shalini Singh has established a professional research profile that combines clinical pharmacology, pharmaceutical regulation, cosmetic compliance, and healthcare quality assurance. Through consistent scholarly publications, interdisciplinary collaboration, and evidence-based regulatory research, she contributes to the advancement of pharmaceutical sciences and responsible healthcare innovation. Her academic achievements, publication metrics, and continuing scientific engagement provide a strong foundation for professional recognition within international pharmaceutical research communities.[1][4]

External Links

References

Google Scholar. (n.d.). Shalini Singh – Google Scholar Profile. https://scholar.google.com/citations?user=N3KRvykAAAAJ
Singh, S., Arya, V., Mishra, R. K., & Rajput, S. K. (2026). Clinical Effectiveness of Naturopathic Therapeutic Approaches in the Management of Polycystic Ovary Syndrome: Real-World Evidence. Current Indian Science. Advance online publication. https://doi.org/10.2174/012210299X481816260630115057
Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., Mishra, S., & Rana, M. (2025). Mechanistic and Phytopharmacological Insights into Ayurvedic Botanicals for the Management of Polycystic Ovarian Syndrome. Journal of Ayurvedic and Herbal Medicine. https://doi.org/10.4103/JAHM.JAHM_55_25
Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., & Dhanasekaran, M. (2024). Nanotechnology in the diagnosis and management of polycystic ovary syndrome: A systematic scoping analysis to improve patient care. Next Research. https://doi.org/10.1016/j.nexres.2024.100004
Balkrishna, A., Rana, M., Mishra, S., Srivastava, D., Bhardwaj, R., Singh, S., Rajput, S. K., Arya, V., & Rigano, D. (2023). Incredible Combination of Lifestyle Modification and Herbal Remedies for Polycystic Ovarian Syndrome Management. Evidence-Based Complementary and Alternative Medicine.
https://doi.org/10.1155/2023/3705508

Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on 21/05/202622/05/2026 by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University

Naglaa Shehab
Affiliation	Dubai Medical University
Country	United Arab Emirates
Scopus ID	26424069600
Documents	446
Citations	494
h-index	13
Subject Area	Drug Discovery and Development
Event	International Top Pharmaceutical Awards
ORCID	0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

Research specialization in pharmacognosy and natural products
Experience in medicinal plant extraction and phytochemical analysis
Editorial and academic participation in pharmaceutical sciences
Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

Development of phytochemical and natural product formulations
Evaluation of anticancer and antioxidant activities
Research on medicinal plant-derived therapeutic compounds
Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

External Links

References

ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
DOI: https://doi.org/10.1371/journal.pone.0308879

Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Published on 31/07/202506/08/2025 by Top Pharmaceutical

Prof. Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Chair Professor at Shanghai Jiao Tong University School of Medicine | China

Prof. Song Guo Zheng, M.D., Ph.D., is an internationally renowned immunologist and clinician-scientist specializing in rheumatology, molecular immunology, and translational medicine. He currently serves as Chair Professor and Dean of the School of Cell and Gene Therapy at Shanghai Jiao Tong University. With academic leadership roles across prestigious institutions in the U.S. and China, his pioneering work spans autoimmunity, cell therapy, and immunoregulation. A prolific author with over 110 peer-reviewed publications in top-tier journals, Prof. Zheng is also a highly decorated researcher and active leader in global immunology societies. His contributions continue to shape modern immunotherapy and precision medicine.

Publication Profile

Google Scholar

Orcid

Education

Prof. Zheng earned his Ph.D. in Molecular Immunology from the University of Orleans, France (2011), and a Master’s in Pathology and Immunology from Shanghai Medical University (1992). He completed his M.D. at Anhui Medical University (1984). His clinical training included a residency in surgery at Chizhou City Hospital (1984–1989) and an internship at Shanghai Zhabei Hospital (1983–1984). He further pursued a pathology fellowship at Shanghai Medical University Cancer Hospital (1989–1993). These academic and clinical foundations laid the groundwork for a distinguished career in immunology, clinical research, and translational medicine across both China and the United States.

Experience

Prof. Zheng currently serves as Chair Professor at Shanghai Jiao Tong University and Dean of the School of Cell and Gene Therapy (2023–Present). He previously held senior positions including the Ronald L. Whisler Chair in Rheumatology and Immunology at Ohio State University (2018–2022) and Director at Penn State University’s College of Medicine (2013–2018). His U.S. academic journey began at the University of Southern California as an assistant and associate professor (2004–2013), after postdoctoral work at USC and UCLA. With leadership in research, teaching, and clinical science, he has become a global authority in immunological therapeutics and rheumatology.

Awards

Prof. Zheng has received numerous prestigious honors, including the Outstanding Scientist Award (2023, USA) and the Distinguished Clinical Immunologist Award (2019, China). He was awarded the Edmund L. Dubois Award (2019), NIH STAR Award (2016–2021), and was Chair of NIH MOSS Study Section (2016). Notably, he earned the James R. Klinenberg Award for best immunologist in Southern California (2007) and the Freda Newton Memorial Scholar Award (2006). He is an elected member of The Henry Kunkel Society (2012) and a recipient of the ACR Investigator Award (2008–2010), reflecting his impactful and sustained contributions to clinical immunology.

Research Focus

Prof. Zheng’s research centers on molecular immunology, particularly in autoimmune diseases, Treg/Th17 cell modulation, and immune tolerance mechanisms. He investigates immunometabolism, gene and cell therapy, and inflammatory signaling pathways with an emphasis on clinical translation. His studies on cytokines, nanomedicine, and immune checkpoint regulation aim to advance precision therapeutics for rheumatic and inflammatory diseases. He integrates cutting-edge techniques including single-cell sequencing, CRISPR-based modulation, and nano-drug delivery systems. His innovative research is highly cited and supports next-generation treatments for autoimmunity, cancer immunotherapy, and organ-specific inflammation, shaping global trends in immune-based medical interventions.

Publication Top Notes

Natural and induced CD4+ CD25+ cells educate CD4+ CD25− cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10

IL-2 is essential for TGF-β to convert naive CD4+ CD25− cells to CD25+ Foxp3+ regulatory T cells and for expansion of these cells

Role of vitamin A in the immune system

Generation ex vivo of TGF-β-producing regulatory T cells from CD4+ CD25− precursors

Vitamin D and chronic diseases

TGF-β requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+ CD25+ regulatory cells

Natural and TGF-β–induced Foxp3+ CD4+ CD25+ regulatory T cells are not mirror images of each other

Role of TNF–TNF receptor 2 signal in regulatory T cells and its therapeutic implications

Cutting edge: Foxp3+ CD4+ CD25+ regulatory T cells induced by IL-2 and TGF-β are resistant to Th17 conversion by IL-6

Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms

The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3

The role of the combination of IL-2 and TGF-β or IL-10 in the generation and function of CD4⁺ CD25⁺ and CD8⁺regulatory T cell subsets

Conclusion

Given his outstanding scientific productivity, leadership in global immunology communities, and groundbreaking research on immune regulation, Prof. Song Guo Zheng is highly suitable for the Best Researcher Award. His body of work demonstrates not only scientific depth and innovation but also sustained impact on the field of immunology and clinical medicine. With ongoing contributions and strategic improvements, he remains a central figure in advancing immune-based therapies and education worldwide.

Efthalia Moustakli | Pharmacology | Best Researcher Award

Published on 22/07/202522/07/2025 by Top Pharmaceutical

Efthalia Moustakli | Pharmacology | Best Researcher Award

Dr. Efthalia Moustakli at University of Ioannina, School of Health Sciences, Greece.

Dr. Efthalia Moustakli, a PhD-trained biologist, excels in medical genetics, molecular biology, and bioinformatics. Currently a postdoctoral researcher and adjunct professor, she integrates clinical, wet-lab, and computational techniques to drive real-world healthcare innovation. With extensive experience in translational science and academic mentorship, she bridges the gap between research and clinical application. Her dedication to advancing reproductive medicine and aging research is reflected in 30+ high-impact publications. Recognized for academic excellence and research leadership, she exemplifies commitment to impactful science and interdisciplinary collaboration across education, technology, and medicine.

Publication Profile

Google Scholar

Education

Dr. Efthalia Moustakli earned her PhD in Medical Genetics from the University of Ioannina, Greece, with her dissertation graded “Excellent” and focused on telomere and mitochondrial recombination in spermatozoa. She previously completed an Integrated Master’s in Biological Applications and Technology, also from the University of Ioannina, where her thesis on genetic abnormalities. Her academic journey reflects a strong foundation in genetics, genomics, and reproductive biology, complemented by international training in Germany, showcasing her commitment to advancing precision and reproductive medicine through rigorous scientific research and interdisciplinary learning.

Experience

Dr. Efthalia Moustakli is currently a Postdoctoral Researcher at the Department of Informatics and Telecommunications, University of Ioannina, focusing on molecular aging and bioinformatics. She also serves as an Adjunct Professor in the Nursing Department. Previously, she worked as a Junior Embryologist at Genesis Athens, a Molecular Biologist on the EU-funded PathAge project, and as a trainee in Germany at Universitätsklinikum Jena. Her experience spans clinical research, wet-lab diagnostics, data analysis, and teaching, highlighting her ability to navigate both academia and real-world clinical settings with excellence and innovation.

Awards

Dr. Efthalia Moustakli has been recognized for her exceptional contributions to reproductive science and molecular biology, earning top academic grades in both her PhD and Integrated Master’s programs. Her work on oxidative stress, microRNAs, and genetic diagnostics has gained international attention through 30+ peer-reviewed publications. She has actively contributed to EU-funded research projects and presented findings at major conferences. Her unique blend of clinical embryology, teaching, and algorithm development distinguishes her as a well-rounded scientist. A strong candidate for the Best Researcher Award, she exemplifies academic rigor, innovation, and interdisciplinary impact.

Research Focus

Dr. Efthalia Moustakli specializes in reproductive health, infertility, oxidative stress, NGS data meta-analysis, and clinical genetics. Her postdoctoral work delves into the molecular mechanisms of aging, particularly in relation to telomeres and mitochondrial function. Through projects like PathAge, she integrates computational approaches with clinical data to enhance diagnostic and therapeutic insights. Her research interests span microbiome impacts, ART (Assisted Reproductive Technology), and biomarkers for reproductive outcomes, aiming to translate molecular findings into practical healthcare improvements. She combines bioinformatics, wet-lab, and clinical insight to support advances in personalized and preventative medicine.

Publication Top Notes

Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Published on 14/07/202514/07/2025 by Top Pharmaceutical

Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Prof. Khaydar Yunusov at Institute of Polymer Chemistry and Physics Uzbekistan Academy of Sciences, Uzbekistan.

Prof. Khaydar Yunusov is a distinguished polymer chemist from Uzbekistan with extensive expertise in nanotechnology, cellulose chemistry, and biomaterials. Since 2007, he has held key research and leadership roles at the Institute of Polymer Chemistry and Physics, contributing significantly to polymer-based biomedical innovations. 💊 He holds a Doctor of Science and leads groundbreaking projects on nanostructured antibacterial films, antiviral eye medications, and burn treatments. 📘 With several patents, international collaborations 🌍, and editorial roles in leading journals, Prof. Yunusov is a pioneering force in sustainable polymer research and nanomedical applications.

Publication Profile

Orcid

Education

Prof. Khaydar Yunusov began his academic journey at the Tashkent Chemical Technological Institute, earning a Bachelor’s degree in Chemistry (2006) and a Master’s in Cellulose, Paper Chemistry, and Technology (2008). 📘 Driven by scientific excellence, he pursued a Doctor of Science in Technical Sciences (2009–2016), focusing on advanced polymer research. Since 2018, he has served as a Senior Scientific Researcher in Nanochemistry, Nanophysics, and Nanotechnology. 🧪 His research delves into nanostructured bactericidal preparations based on cellulose and its derivatives, emphasizing synthesis, properties, and production technologies. 🧬 His academic background provides a solid foundation for pioneering innovations in polymer science.

Experience

Prof. Khaydar Yunusov has cultivated a rich professional career in polymer science, beginning in 2007 as a researcher at the Institute of Polymer Chemistry and Physics, Uzbek Academy of Sciences, Tashkent. 📍 Over the years, he advanced through roles including junior researcher, senior researcher, and project manager, earning his Doctor of Science along the way. 🔬 His expertise spans polymer and cellulose chemistry, nanotechnology, and biomaterials. From 2019 to 2023, he served as a lab and project manager, driving innovation in nanostructured materials. 💼 Prof. Yunusov’s professional path reflects unwavering dedication to scientific discovery and technological advancement.

Research Focus

Prof. Khaydar Yunusov is a pioneering scientist whose research spans polymer chemistry, cellulose technology, and nanochemistry. His core focus lies in designing biocompatible nanomaterials 🧫 such as nanostructured drug delivery systems, microneedles, hydrogels, and functional films for medical applications 🎯. He actively explores biodegradable polymers, nanoparticle synthesis (silver, selenium, zinc oxide), and antimicrobial and anticancer therapies 💊. His work intersects biotechnology, materials science, and pharmaceutical engineering, advancing targeted treatments and regenerative medicine 🧠🦠. With numerous high-impact publications, Prof. Yunusov is shaping the future of smart biomaterials and sustainable polymeric solutions.

Publication Top Notes

A red cell membrane-camouflaged nanoreactor for enhanced starvation/chemodynamic/ion interference therapy for breast cancer

A three-dimensional printable conductive composite dressing for accelerating wound healing under electrical stimulation

Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management ( vol 12, pg 1064, 2024)

Fabrication of hollow microneedles with double-layer shell structure for rapid and prolonged local anesthesia

Homemade isothermal amplification-initiated Cas14a assay for rapid quantitative detection of aquatic RNA virus gene with no PAM

Iontophoresis-driven transdermal drug delivery system based on porous microneedles for hyperuricemia treatment

Real-time microbial growth curve (RMGC) system: an improved microplate reader with a graphical interface for automatic and high-throughput monitoring of microbial growth curves

Two-directions mechanical strength and high-barrier mechanisms of cellulose nanocrystal- based hybrids reinforced packaging with nacre-mimetic structure

Physico-chemical characteristics of dialdehyde carboxymethylcellulose/sericin graft copolymer

Synthesis, Characterization, and Cytotoxic Activity of Stable Selenium Nanoparticles‐Incorporated Carboxymethylcellulose Solution

Impact of cellulose supramolecular structure on its carboxymethylation reaction activity

Advances in the formation and properties of nanofiber biomaterials from polyvinyl alcohol/carboxymethylcellulose/nanosilver systems for medical applications

Obtaining Dialdehyde Carboxymethylcellulose Through Microwave Treatment

Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on 08/07/202508/07/2025 by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections

Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde

Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation

Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study

Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption

A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6

C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Belal Hijji | Pharmacology | Best Researcher Award

Published on 05/05/202505/05/2025 by Top Pharmaceutical

Belal Hijji | Pharmacology | Best Researcher Award

Assist. Prof. Dr. Belal Hijji, Prince Sattam Bin Abdulaziz University, Saudi Arabia

Assistant Professor Dr. Belal Hijji is a distinguished nursing academic with a Ph.D. in Adult Health Nursing from the University of Ulster, UK. He has served in academic and clinical roles across Jordan, Saudi Arabia, Libya, and the UAE. With a strong focus on blood transfusion safety, he has authored books and peer-reviewed articles, including in Journal of Clinical Nursing and Nursing Reports. Dr. Hijji is passionate about nursing education, patient safety, and ethical research, and is fluent in both Arabic and English. He currently teaches at Prince Sattam bin Abdulaziz University, KSA.

Publication Profile

Google Scholar

Education

Assist. Prof. Dr. Belal Hijji is a distinguished academic with a robust background in nursing education and research. He earned his Bachelor of Nursing from Yarmouk University, Jordan (1983–1987), followed by an MSc in Nursing Studies from the University of Manchester, UK (1999–2001), where he conducted a thesis on students’ perceptions of nursing as a career. He later achieved a Ph.D. in Adult Health Nursing from the University of Ulster, UK (2003–2007), focusing on blood transfusion practices among nurses in Abu Dhabi. 🧠 In 2017, he also earned certification in human research participant protection from the NIH.

Awards

Assist. Prof. Dr. Belal Hijji has enriched his professional journey through a variety of specialized training courses. His early learning included managing hypertension and heart failure (1987) and infection control in London (1996). 🏥 He attended the 2nd GCC Seminar on Gerontology in Abu Dhabi (1997) and gained critical appraisal skills in Oxford (2000). He also participated in conferences on healthcare ethics (2002), medical statistics (2004), and qualitative research at the University of Ulster. 📊 His continuous learning extended through webinars on learning psychology (2022) and contributing to the UN Sustainable Development Goals (2022). 🌍 Lifelong learning remains his driving force.

Experience

Assist. Prof. Dr. Belal Hijji has held numerous academic and clinical roles across the Arab world. Since September 2019, he has served as Assistant Professor of Nursing at Prince Sattam bin Abdulaziz University, KSA. 🇸🇦 Previously, he taught at Al Ghad International Colleges (2015–2019), Benghazi University, Libya (2012–2015), and the University of Ha’il (2011–2012). 🏫 Earlier roles include Assistant Professor at Philadelphia University, Jordan (2008–2010). From 1987 to 2005, he worked in diverse clinical and administrative positions within regional ministries of health. 🏥 His leadership also included overseeing scientific affairs and curriculum development. 📘 His dedication to nursing education spans decades.

Research Focus

Assistant Professor Dr. Belal Hijji’s research primarily centers on blood transfusion knowledge and safety among nurses, with a strong emphasis on nursing education, clinical practice, and assessment tools. His studies span diverse healthcare settings in Jordan and the UAE, investigating nurses’ competencies, transfusion practices, and educational gaps. Additionally, he explores the effectiveness of assessment tools like multiple-choice questions and mathematical skills in dosage calculation, highlighting critical aspects of nursing proficiency. Through observational studies and survey research, Dr. Hijji contributes valuable insights into improving patient safety and enhancing nursing curricula.

Publication Top Notes

Knowledge of blood transfusion among nurses

Measuring knowledge of blood transfusion: A survey of Jordanian nurses

Nurses’ practice of blood transfusion in the United Arab Emirates: an observational study

Flaws of multiple choice questions in teacher-constructed nursing examinations: A pilot descriptive study

Trained nurses’ knowledge and practice of oral care on three wards in acute care hospital in Abu Dhabi, UAE

Item Analysis of the Modified Version of the Routine Blood Transfusion Knowledge Questionnaire

Knowledge and practice of blood transfusion: A survey of nurses in Abu Dhabi, United Arab Emirates

An Indispensable Requirement for Medical Dosage Calculation: Basic Mathematical Skills of Baccalaureate Nursing Students

The Science of Multiple-Choice Questions (MCQs)

Lior Zangi | Drug Discovery and Development | Best Researcher Award

Published on 03/05/202503/05/2025 by Top Pharmaceutical

Lior Zangi | Drug Discovery and Development | Best Researcher Award

Prof. Lior Zangi, Icahn School of Medicine at Mount Sinai, United States

Prof. Lior Zangi is an Associate Professor of Cardiology and Genetics & Genomic Sciences at the Icahn School of Medicine at Mount Sinai, NY. He earned his Ph.D. in Immunology from the Weizmann Institute and completed postdoctoral training at Harvard Medical School. Renowned for his pioneering work in mRNA-based cardiovascular therapies, Prof. Zangi has received prestigious awards including the AHA Postdoctoral Fellowship and an endowed professorship in Cardiovascular Research. He is a founding board member of the Society for RNA Therapeutics and actively contributes to global scientific councils, manuscript reviews, and grant panels.

Publication Profile

Google Scholar

Education

Prof. Lior Zangi 🎓 began his academic journey with a B.Sc. in Biology from the Hebrew University, Givat-Ram, Jerusalem in 2000. He then earned his M.Sc. in Experimental and Developmental Medicine in 2003 from the Hebrew University Hadassah-Medical School under the guidance of Prof. Raphael Gorodetsky. In 2009, he completed his Ph.D. in Immunology at the Weizmann Institute of Science, mentored by Prof. Yair Reisner. 🌿 He continued his training as a postdoctoral fellow at Sheba Medical Center (2009–2010) under Prof. Benjamin Dekel and later at Harvard Medical School (2010–2014) with Professors Derrick Rossi and Kenneth Chien.

Awards

Prof. Lior Zangi 🌟 has earned numerous prestigious honors throughout his career. He received the ASH Travel Award in both 2008 and 2009 🧳, and in 2009, was granted a Postdoctoral Fellowship Award by the Israeli Budgeting Committee and Planning. In 2012, he was honored with both the ISSCR Travel Award and R&D Systems Travel Grant ✈️. His groundbreaking postdoctoral work earned him the AHA Fellowship Award in 2014 🫀. In 2017, he received the Mount Sinai Faculty Idea Prize 🧠, and in 2019, his research on mRNA therapy was recognized as highly influential 📜. In 2023, he was awarded the Endowed Chan Soon-Shiong Professorship in Cardiovascular Research 🏅.

Research Focus

Prof. Lior Zangi is a pioneering researcher in cardiovascular regenerative medicine, with a special focus on modified mRNA therapies, 🧬 stem cell biology, and 🫀 cardiac regeneration. His work centers on developing innovative strategies for repairing damaged heart tissue using modRNA, induced pluripotent stem cells (iPSCs), and heart-on-chip technologies. Zangi’s groundbreaking research has contributed to advancements in treating conditions like myocardial infarction and Barth syndrome, and has broad implications for tissue engineering, 💉 protein replacement therapy, and immune modulation. His contributions are reshaping modern precision medicine and offering new hope for heart failure patients worldwide.

Publication Top Notes

Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies

Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction

Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads

Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells

A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells

Isolation and characterization of nontubular sca-1+ lin− multipotent stem/progenitor cells from adult mouse kidney

Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration

mRNA-based protein replacement therapy for the heart

Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction

Nitika Mor | Drug Discovery and Development | Best Researcher Award

Published on 03/05/202503/05/2025 by Top Pharmaceutical

Nitika Mor | Drug Discovery and Development | Best Researcher Award

Dr. Nitika Mor, Baba Mastnath University, Asthal Bohar, Rohtak (HR), India

Dr. Nitika Mor is an accomplished Assistant Professor of Chemistry at Baba Mastnath University, Rohtak, with a Ph.D. in Pharmaceutical Chemistry from Kurukshetra University. Her research focuses on drug delivery systems, traditional medicinal formulations, and molecular docking. She has published 14 research papers, authored a book chapter, holds two patent publications (one granted), and has received multiple awards including the UGC-CSIR JRF/SRF and Best Poster Award. With technical expertise in synthesis, biological assays, and in-silico studies, Dr. Mor is a dynamic contributor to pharmaceutical research and innovation.

Publication Profile

Google Scholar

Education

Dr. Nitika Mor is a dedicated researcher with a Ph.D. in Chemistry from Kurukshetra University (2017–2022), where she focused her thesis on the Design, Characterization, and In-Vitro Studies of Sustained Release Delivery Systems for Curcumin under the guidance of Dr. Neera Raghav. 🎓 She holds an M.Sc. in Organic Chemistry (2013–2015) from Hindu College, Sonipat, affiliated with Maharishi Dayanand University, Rohtak. 🧪 Her academic journey began with a B.Sc. in Physics, Chemistry, and Mathematics (2010–2013) from Hindu Girls College, Sonipat. 📚 Dr. Mor’s educational background reflects a strong foundation in science and innovative pharmaceutical research.

Experience

Dr. Nitika Mor is currently serving as an Assistant Professor in the Department of Chemistry at Baba Mastnath University, Rohtak, since February 1, 2023. 🏛️ With her strong academic foundation and research expertise in pharmaceutical and organic chemistry, she brings innovative teaching methods and deep subject knowledge to the classroom. 🧪 Her role involves mentoring students, delivering engaging lectures, and contributing to the academic growth of the department. 📚 Dr. Mor’s commitment to education and passion for chemistry make her a valuable asset to the university’s faculty. ✨ She continues to inspire budding scientists through her teaching and guidance.

Awards

Dr. Nitika Mor has received several prestigious awards and fellowships in recognition of her academic excellence and research potential. She qualified the UGC-CSIR JRF (Chemical Sciences) in June 2016 with an impressive All India Rank of 65. 🇮🇳 She was awarded the Junior Research Fellowship (JRF) from October 2017 to September 2019, followed by the Senior Research Fellowship (SRF) from October 2019 to March 2022 by UGC-CSIR India to support her Ph.D. journey. 🔬 In 2018, she received the Best Poster Presentation Award at the 9th National Conference on RACES-2018 held at MMM College, Patiala, Punjab.

Research Focus

Dr. Nitika Mor specializes in pharmaceutical and biomedical sciences, with a strong research focus on natural polymer-based oral drug delivery systems. Her work emphasizes the use of biopolymers like cellulose, pectin, carrageenan, and alginate for sustained release formulations, particularly for curcumin. She explores modifications of polysaccharides and curcumin derivatives to improve bioavailability, pharmacokinetics, and therapeutic efficacy. Her contributions also span phytochemistry, investigating medicinal plants like Ashwagandha and Garlic for their pharmacological benefits. Dr. Mor integrates green chemistry, molecular modeling, and clinical insights into her innovative drug delivery strategies.